FDA approves only vaccine Penbraya for treatment of meningococcal disease in adolescents
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Subscribe To Our Newsletter & Stay Updated